Identification of cytochrome P450 enzymes responsible for N -dealkylation of a new oral erectogenic, mirodenafil

References

• Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Ketoconazole and sulfaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica 1995; 25: 261–270
   PubMed Web of Science ®Google Scholar
• Gibson GG, Plant NJ, Swales KE, Ayrton A, El-Sankary W. Receptor-dependent transcriptional activation of CYP3A genes: Induction mechanisms, species differences and interindividual variation in man. Xenobiotica 2002; 32: 165–206
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annual Review of Pharmacology and Toxicology 1999; 39: 1–117
   PubMed Web of Science ®Google Scholar
• Hedaya MA, El-Afify DR, El-Maghraby. The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. Biopharmaceutics and Drug Disposition 2006; 27: 103–110
   PubMed Web of Science ®Google Scholar
• Hyland R, Roe EGH, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. British Journal of Clinical Pharmacology 2001; 51: 239–248
   PubMed Web of Science ®Google Scholar
• Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, Wojnowski L. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metabolism and Disposition 2002; 30: 1108–1114
   PubMed Web of Science ®Google Scholar
• Lee JI, Yoo HH, Rhim KJ, Sohn DR, Kim DH. Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxy-ethyl)-piperazine-1-sulfonyl]-2-propoxy-phenyl}-7-propyl-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one (SK3530) in rats. Rapid Communications in Mass Spectrometry 2007; 21: 1139–1149
   PubMed Web of Science ®Google Scholar
• Merry C, Barry MG, Ryan M, Tjia JF, Hennesy M, Eagling VA, Mulcahy F, Back DJ. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS 1999; 13: F101–F107
   PubMed Web of Science ®Google Scholar
• Moon Y, Kim SY, Ji HY, Kim YK, Chae HJ, Chae SW, Lee HS. Characterization of cytochrome P450s mediating ipriflavone metabolism in human liver microsomes. Xenobiotica 2007; 37: 246–259
   PubMed Web of Science ®Google Scholar
• Muirhead GJ, Faulkner S, Harness JA, Taubel J. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil citrate in healthy volunteers. British Journal of Clinical Pharmacology 2002; 53: 37S–43S
   Web of Science ®Google Scholar
• Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. British Journal of Clinical Pharmacology 2000; 50: 99–107
   PubMed Web of Science ®Google Scholar
• Newton DJ, Wang RW, Lu AY. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition 1995; 23: 154–158
   PubMed Web of Science ®Google Scholar
• Oh JG, Jang WJ, Chi SC. Validation of a HPLC method for the quantification and purity determination of SK3530 in drug substance and tablet. Journal of Pharmaceutical and Biomedical Analysis 2007; 43: 1179–1184
   PubMed Web of Science ®Google Scholar
• Plant NJ, Gibson GG. Evaluation of the toxicological relevance of CYP3A4 induction. Current Opinion in Drug Discovery and Development 2003; 6: 50–56
   PubMed Web of Science ®Google Scholar
• Rae JM, Soukhova NV, Flockhart DA, Desta Z. Triethylenethiophosphamide is a specific inhibitor of cytochrome P-450 2B6: Implications for cyclophosphamide metabolism. Drug Metabolism and Disposition 2002; 30: 520–530
   Web of Science ®Google Scholar
• Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, De la Torre R, Davies DS. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. British Journal of Clinical Pharmacology 1990; 29: 651–663
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Suzuki H, Kneller MB, Haining RL, Trager WF, Rettie AE. (+)-N-3-Benzyl-nirvanol and (–)-N-3-benzyl-phenobarbital: New potent and selective in vitro inhibitors of CYP2C19. Drug Metabolism and Disposition 2002; 30: 235–239
   PubMed Web of Science ®Google Scholar
• Von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz, JS, Shader RI. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir. Journal of Clinical Pharmacology 1998; 38: 106–111
   PubMed Web of Science ®Google Scholar
• Von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxeteine, norfluoxeteine, and by azole antifungal agents. Journal of Clinical Pharmacology 1996; 36: 783–791
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS, Gaman EA, Gleeson JPR, Proctor WR. Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metabolism and Disposition 2005; 33: 413–418
   PubMed Web of Science ®Google Scholar
• Wang JS, Wen X, Backman JT, Taavitsainen P, Neubonnen PJ, Kivisto KT. Midazolam α-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacology and Toxicology 1999; 85: 157–161
   PubMedGoogle Scholar
• Warrington JS, Shader RI, Von Moltke LL, Greenblatt DJ. In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions. Drug Metabolism and Disposition 2000; 28: 392–397
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Thummel KE. CYP3A. Metabolic drug interactions, RH Levy, KE Thummel, WF Trager, PD Hansten, M Eichelbaum. Lippincott Williams & Wilkins, Philadelphia, PA 2000; 115
   Google Scholar
• Yoo H-H, Kim N-S, Im G-J, Kim D-H. Pharmacokinetics and tissue distribution of a novel PDE5 inhibitor, SK3530, in rats. Acta Pharmacologica Sinica 2007; 28: 1247–1253
   PubMed Web of Science ®Google Scholar
• Yun CH, Shimada T, Guengerich FP. Purification and characterization of human liver microsomal cytochrome P450 2A6. Molecular Pharmacology 1991; 40: 679–685
   PubMed Web of Science ®Google Scholar